Market Research Logo

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

About Autoimmune and Inflammatory Immunomodulators

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.

Technavio’s analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer
Other prominent vendors
  • AstraZeneca
  • Avaxia Biologics
  • Biogen Idec
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Eli Lilly
  • Enlivex Therapeutics
  • Gilead Sciences
  • Immune Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe Pharma
  • Neovacs
  • Prometheus Laboratories
  • Sandoz
  • Sanofi
  • Swedish Orphan Biovitrum
  • Takeda Pharmaceuticals
  • UCB
Market driver
  • Development of novel therapies using innovative technologies.
  • For a full, detailed list, view our report
Market challenge
  • Discontinuation of drugs under development leading to substantial loss in revenue.
  • For a full, detailed list, view our report
Market trend
  • Advent of biosimilars expected to improve the treatment rates.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

Technavio recognizes the following companies as the key players in the global autoimmune and inflammatory immunomodulators market: AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer.

Other prominent vendors in the market are: AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.

Commenting on the report, an analyst from Technavio’s team said: “One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future.”

According to the report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie's Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY). The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn's disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies).

Further, the report states that one major challenge in the market is discontinuation of drugs under development leading to substantial loss of revenue. Discontinuation of the drugs under development or from the market after its launch due to non-satisfactory safety or efficacy result is a major challenge for the market. Discontinuation in the late stages of development or from the market will lead to a heavy loss in revenues because of the high R&D and marketing costs invested by the company. Discontinuation of rheumatoid arthritis and IBD drugs is high as the drug target is not properly understood before the drug trial commences. Also, the drugs are sometimes discontinued at the later stages of the trial as unacceptable adverse effects appear on the body.



Companies Mentioned

AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, UCB.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Different classes of immunosuppressant drugs based on their mechanism of action
      • Table Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015
      • Table Key customer segments of autoimmune and inflammatory immunomodulators market
  • Autoimmune and inflammatory diseases
    • Table Etiology of autoimmune diseases
    • Rheumatoid arthritis
    • IBD
    • Top immunomodulators for rheumatoid arthritis and IBD
  • Pipeline portfolio
    • Table Pipeline portfolio: Rheumatoid arthritis immunomodulators
    • Table Pipeline portfolio: Ulcerative colitis immunomodulators
    • Table Pipeline portfolio: Crohn's disease immunomodulators
  • Market landscape
    • Market overview
      • Table Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015
    • Market size and forecast
      • Table Factors influencing global autoimmune and inflammatory immunomodulators market
      • Table Approval and patent expiries of top-selling biologics
      • Table Impact of factors affecting the market 2015 and 2020
      • Table Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of disease
    • Table Segmentation of global autoimmune and inflammatory immunomodulators by type of disease
    • Table Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020
    • Global rheumatoid arthritis immunomodulators market
      • Table Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
      • Table Opportunities across rheumatoid arthritis industry
    • Global IBD immunomodulators market
      • Table Global IBD immunomodulators market 2015-2020 ($ billions)
      • Table Global IBD therapeutics market segmentation growth lifecycle analysis
      • Table Global IBD immunomodulators market by disease type 2015-2020
      • Table Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
      • Table Global Crohn's disease immunomodulators market 2015-2020 ($ billions)
  • Market segmentation by molecule type
    • Table Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions)
    • Global autoimmune and inflammatory biologic immunomodulators market
      • Table Global autoimmune and inflammatory biologic immunomodulators market 2015- 2020 ($ billions)
      • Table Biologicals approvals by the US FDA
      • Table Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
      • Table Global IBD biologic immunomodulators market 2015-2020 ($ billions)
    • Global autoimmune and inflammatory small molecule immunomodulators market
      • Table Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions)
  • Geographical segmentation
    • Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
      • Table Global autoimmune and inflammatory immunomodulators market by geography 2015-2020
      • Table Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions)
      • Table Global share of autoimmune and inflammatory immunomodulators market by geography 2015
      • Table Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015
      • Table Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate
    • Autoimmune and inflammatory immunomodulators market in Americas
      • Table Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas
      • Table Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions)
    • Autoimmune and inflammatory immunomodulators market in EMEA
      • Table Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA
      • Table Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions)
    • Autoimmune and inflammatory immunomodulators market in APAC
      • Table Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC
      • Table Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Strong adoption of TNF-alpha inhibitors and B-cell inhibitors
      • Table Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
    • Development of novel therapies using innovative technologies
      • Table Key vendors: Developing novel therapies
    • Improved diagnostic tools increase the treatment-seeking population
      • Table Key developments leading to improved diagnostics
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Discontinuation of drugs under development leading to substantial loss of revenue
      • Table List of few immunomodulators that were discontinued from development or market
    • Growing popularity of alternative treatment procedures hinders the market growth
      • Table CAM therapies for rheumatoid arthritis
      • Table Usage of CAM therapies in US adults
      • Table List of CAM therapies and items used in Crohn's disease and ulcerative colitis
    • Adverse effects of the drugs
      • Table List of adverse side effects associated with rheumatoid arthritis
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of oral agents likely to improve patient outcomes
      • Table Key marketed and pipeline oral agents
    • Advent of biosimilars expected to improve the treatment rates
      • Table List of few biosimilars under development for various indications
    • Focus on regenerative medicines
      • Table List of few regenerative medicines under development for rheumatoid arthritis and IBD
    • Strategic alliances and acquisitions
      • Table Key deals in global immunomodulators market
  • Vendor landscape
    • Competitive scenario
      • Table Market share of key vendors 2015
      • Table Geographical presence of key vendors
      • Table Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020
    • Other prominent vendors
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
      • Table AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
    • Johnson & Johnson
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
      • Table Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
    • Amgen
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
      • Table Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions)
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
      • Table F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions)
    • Pfizer
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report